Transplacental mutagenicity of cisplatin: H-ras codon 12 and 13 mutations in skin tumors of SENCAR mice

Carcinogenesis

Volumn 17, Issue 12, 1996, Pages 2741-2745

  Munoz, Eliana F ^a   Diwan, Bhalchandra A ^a   Calvert, Richard J ^b   Weghorst, Christopher M ^c,d   Anderson, John ^c   Rice, Jerry M ^c   Buzard, Gregory S ^a  

^a SAIC FREDERICK INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; CISPLATIN; DINUCLEOTIDE; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CODON; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DNA SEQUENCE; EXON; FEMALE; FETUS RISK; GENE MUTATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MUTAGENICITY; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CODON; FEMALE; FETUS; GENES, RAS; MICE; MUTAGENS; MUTATION; PREGNANCY; SKIN NEOPLASMS;

EID: 0030460578     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.12.2741     Document Type: Article

References (32)

1. Greene,M.H. (1992) Is cis-platin a human carcinogen? J. Natl Cancer lnst., 84, 306-312.
2. Malfetano,J.H. and Goldkrand,J.W. (1990) Cis-platinum combination chemotherapy during pregnancy for advanced epithelial ovarian carcinoma. Obster. Gynecol., 75, 545-547.
3. Raffles,A., Williams,J., Costeloe,K. and Clark,P. (1989) Transplacental effects of maternal cancer chemotherapy. Case report. Br. J. Obstet. Gynaecol., 96, 1099-1100.
4. Ben-Baruch,G., Menczer,J., Goshen,R., Kaufman,B. and Gorodetsky,R. (1992) Cisplatin excretion in human milk. J. Natl Cancer Inst., 84, 451-452.
5. Waalen,J. (1991) Pregnancy poses tough questions for cancer treatment. J. Natl Cancer Inst., 83, 900-902.
6. Turnbull,D., Popescu,N.C. DiPaolo,J.A. and Myhr,B.C. (1979) Cis-platinum(II) diammine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells. Mutat. Res., 66, 267-275.
7. Taylor,R.T., Carver,J.H., Hanna,M.L. and Wandres,D.L. (1979) Platinum-induced mutations to 8-azaguanine resistance in Chinese hamster ovary cells. Mutat. Res., 67, 65-80.
8. Barnhardt,C.M. and Bowden,G.T. (1985) Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer Lett., 29, 101-105.
9. Diwan,B.A., Anderson,L.M., Rehm,S. and Rice,J.M. (1993) Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice. Cancer Res., 53, 3874-3876.
10. Diwan,B.A., Anderson,L.M., Ward,J.M., Henneman,J.R. and Rice,J.M. (1995) Transplacental carcinogenesis by cis-platin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol. Appl. Pharmacol., 132, 115-121.
11. Shamkhani,H. et al. (1994) DNA adducts in human and Patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod. Toxicol., 8, 207-216.
12. Quintanilla,M., Brown,K., Ramsden,M. and Balmain,A. (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature, 322, 78-80.
13. Bizub,D., Wood,A.W. and Skalka,M. (1986) Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc. Natl Acad. Sci. USA, 83, 6048-6052.
14. Nelson,M.A., Futsher,B.W., Kinsella,T., Wymer,J. and Bowden,G.T. (1992) Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors. Proc. Natl Acad. Sci. USA, 89, 6399-6402.
15. Loktionov,A., Hollestein,M., Martel,N., Galendo,D., Cabral,R.P., Tomatis,L. and Yamasaki,H. (1990) Tissue-specific activating mutations of Ha-ras and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA. Mol. Carcinogen., 3, 134-140.
16. Loktionov,A., Popovich,I., Zabezinski,M., Martel,N., Yamasaki,H. and Tomatis,L. (1992) Transplacental and transgeneration carcinogenic effect of 7,12-dimethylbenz[a]anthracene: relationship with ras oncogene activation. Carcinogenesis, 13, 19-24.
17. Nelson,M.A., Futscher,B.W., Loew,M.R. and Bowden,G.T. (1992) Analysis of the Harvey ras gene in cisplatin-initiated mouse skin tumors by polymerase chain reaction and direct DNA sequencing. Cancer Lett., 65, 27-33.
18. Park,J.S., Leake,J.F., Sharma,B.K., Toki,T., Kessis,T.D., Ambros,R.A. and Shah,K.V. (1991) Variability in B-globin and HPV DNA amplification by PCR from fixed tissues. Mol. Pathol., 4, 667-670.
19. Cnou,Q., Russel,M., Birch,D.E., Raymond,J. and Bloch,W. (1992) Prevention of pre-PCR mispriming and primer dimerization improves low-copy-number amplifications. Nucleic Acids Res., 20, 1717-1723.
20. Sarkar,G. and Sommer,S.S. (1990) The 'Megaprimer' method of site-directed mutagenesis. BioTechniques, 8, 404-107.
21. Hongyo,T., Buzard,G.S., Calvert,R.J. and Weghorst,C.M. (1993) 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res., 21, 3637-3642.
22. Calvert,R.J., Weghorst,C.M. and Buzard,G.S. (1995) PCR amplification of silver-stained SSCP bands from cold SSCP gels. BioTechniques, 18, 782-786.
23. Wood,M.L. and Eissigmann,J.M. (1991) Molecular mechanisms by which carcinogen - DNA adducts cause mutations. In Origins of Human Cancer: A Comprehensive Review. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 137-148.
24. de Boer,J.G. and Glickman,B.W. (1989) Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene. Carcinogenesis, 10, 1363-1367.
25. Cariello,N.F., Swenburg,J.A. and Skopek,T.R. (1992) In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res., 52, 2866-2873.
26. Bradky,L.J.N., Yarema,K.J., Lippard,S.J. and Essigmann,J.P. (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 32, 982-988.
27. Yarema,K.J., Wilson,J.M., Lippard,S.J. and Essigmann,J.M. (1994) Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. J. Mol. Biol., 236, 1034-1048.
28. Pillaire,M.J., Margot,A., Villani,G., Sarasin,A., Defais,M. and Gentil,A. (1994) Mutagenesis in monkey cells of a vector containing a single d(GpG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acids Res., 22, 2519-2524.
29. Huang,J.-C., Zamble,D.B., Reardon,J.T., Lippard,S.J. and Sancar,A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl Acad. Sci. USA, 91, 10394-10398.
30. Brandsma,J.A., d Ruijter,M., Visse,R., van Meerten,D., van der Kaaden,M., Moggs,J.G. and van de Putte,P. (1996) The in vitro more efficiently repaired cisplatin adduct cis-Pt.GG is in vivo more mutagenic lesion than the relatively slowly repaired cis-Pt.GCG adduct. Mutat. Res., 362, 29-40.
31. Ha gene. Carcinogenesis, 15, 1975-1978.
32. DiGiovanni,J., Beltran,L., Rupp,A., Harvey,R.G. and Gill,R.D. (1993) Further analysis of cHa-rcu mutations in papillomas initiated by several polycyclic aromatic hydrocarbons and papillomas from uninitiated, promoter-treated skin in SENCAR mice. Mol. Carcinogen., 8, 272-279.